Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine Q1 net product sales rise 44% to $811.0 million; GAAP EPS $1.91

Positive Impact 4 of 5 earnings Written later

Neurocrine Biosciences reported first-quarter 2026 total revenues of $814.5 million, up 42% from a year earlier, and GAAP diluted earnings of $1.91 per share versus $0.08 a year earlier. The company reaffirmed its 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion and said it expects to close its $2.9 billion acquisition of Soleno Therapeutics in the second quarter of 2026.

Key points

  • Total net product sales were $811.0 million, up 44% year over year; INGREZZA contributed $656.9 million (up 20%) and CRENESSITY contributed $153.3 million, versus $14.5 million a year earlier.
  • GAAP net income was $197.9 million, or $1.91 per diluted share, compared with $7.9 million, or $0.08, in the first quarter of 2025.
  • Non-GAAP diluted EPS was $1.94, compared with $0.70 a year earlier.
  • Full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion was reaffirmed; the Soleno Therapeutics deal is at $53.00 per share in cash and is expected to close in Q2 2026.

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECMay 5, 2026, 4:02 PM ET
Accession number0000914475-26-000025

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.